CY1110272T1 - Αθανατοποιημενες κυτταρικες σειρες πτηνων για παραγωγη ιου - Google Patents

Αθανατοποιημενες κυτταρικες σειρες πτηνων για παραγωγη ιου

Info

Publication number
CY1110272T1
CY1110272T1 CY20081101019T CY081101019T CY1110272T1 CY 1110272 T1 CY1110272 T1 CY 1110272T1 CY 20081101019 T CY20081101019 T CY 20081101019T CY 081101019 T CY081101019 T CY 081101019T CY 1110272 T1 CY1110272 T1 CY 1110272T1
Authority
CY
Cyprus
Prior art keywords
production
cell lines
virus production
cell series
bird cell
Prior art date
Application number
CY20081101019T
Other languages
English (en)
Inventor
Volker Sandig
Ingo Jordan
Original Assignee
Probiogen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34400514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1110272(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Probiogen Ag filed Critical Probiogen Ag
Publication of CY1110272T1 publication Critical patent/CY1110272T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10251—Methods of production or purification of viral material
    • C12N2710/10252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Manufacturing & Machinery (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε αθανατοποιημένες κυτταρικές σειρές πτηνών κατάλληλες για την παραγωγή βιολογικών προϊόντων ή ιών για εμβολιασμό. Συγκεκριμένα, οι κυτταρικές σειρές προέρχονται από πρωτοταγή κύτταρα τα οποία μετασχηματίζονται με τουλάχιστον δύο ιικά ή κυτταρικά γονίδια, ένα από τα οποία προκαλεί πρόοδο του κυτταρικού κύκλου ενώ το άλλο παρεμβαίνει στους φυσικούς προστατευτικούς μηχανισμούς του κυττάρου που προκαλείται από λανθασμένα ρυθμισμένη αντιγραφή. Η εφεύρεση επιπλέον αναφέρεται στην παραγωγή των εν λόγω αθανατοποιημένων κυτταρικών σειρών και στη χρήση τους για την παραγωγή βιολογικών προϊόντων ή ιών για εμβολιασμό.
CY20081101019T 2003-11-03 2008-09-18 Αθανατοποιημενες κυτταρικες σειρες πτηνων για παραγωγη ιου CY1110272T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03025158A EP1528101A1 (en) 2003-11-03 2003-11-03 Immortalized avian cell lines for virus production
EP04798154A EP1685243B1 (en) 2003-11-03 2004-11-03 Immortalized avian cell lines for virus production

Publications (1)

Publication Number Publication Date
CY1110272T1 true CY1110272T1 (el) 2015-01-14

Family

ID=34400514

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101019T CY1110272T1 (el) 2003-11-03 2008-09-18 Αθανατοποιημενες κυτταρικες σειρες πτηνων για παραγωγη ιου

Country Status (18)

Country Link
US (2) US8940534B2 (el)
EP (4) EP1528101A1 (el)
JP (1) JP4658953B2 (el)
KR (1) KR101027755B1 (el)
CN (1) CN1934243B (el)
AT (2) ATE460473T1 (el)
AU (1) AU2004285089B2 (el)
BR (1) BRPI0415622B8 (el)
CA (1) CA2544462C (el)
CY (1) CY1110272T1 (el)
DE (2) DE602004025996D1 (el)
DK (2) DK1939281T4 (el)
ES (1) ES2309578T3 (el)
PL (1) PL1685243T3 (el)
PT (1) PT1685243E (el)
RU (1) RU2359999C2 (el)
SI (1) SI1685243T1 (el)
WO (1) WO2005042728A2 (el)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2531565C (en) * 2003-07-22 2014-02-11 Vivalis Production of poxviruses with adherent or non adherent avian cell lines
DE602005024827D1 (de) 2004-09-09 2010-12-30 Novartis Vaccines & Diagnostic Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen
CN101365480B (zh) 2005-11-01 2014-11-05 诺华疫苗和诊断有限两合公司 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗
CN102727885A (zh) 2005-11-04 2012-10-17 诺华疫苗和诊断有限公司 包含颗粒佐剂和免疫增强剂组合的流感疫苗
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
US20110180430A1 (en) 2005-11-04 2011-07-28 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines including cytokine-inducing agents
JP2009514844A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル スプリットインフルエンザワクチン用のアジュバントとしての遊離水相界面活性剤を含むエマルション
WO2007052155A2 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
EP1783210A1 (en) * 2005-11-08 2007-05-09 ProBioGen AG Productivity augmenting protein factors, novel cell lines and uses thereof
KR20110110853A (ko) 2006-01-27 2011-10-07 노파르티스 파르마 아게 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
CA2646349A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP3456348A1 (en) 2006-09-11 2019-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
CA2671629C (en) 2006-12-06 2017-08-15 Novartis Ag Vaccines including antigen from four strains of influenza virus
EP1985305A1 (en) * 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
CA2692200A1 (en) 2007-06-27 2008-12-31 Novartis Ag Low-additive influenza vaccines
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
KR101528379B1 (ko) * 2007-07-03 2015-06-16 트랜스진 에스.에이. 불멸화된 조류 세포주들
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
WO2009081172A1 (en) 2007-12-24 2009-07-02 Novartis Ag Assays for adsorbed influenza vaccines
EP2257622B1 (en) * 2008-02-25 2017-03-22 Nanotherapeutics, Inc. Method for producing continuous cell lines
US8679839B2 (en) * 2008-03-04 2014-03-25 Probiogen Ag Cell line from rousettus as host cell for pathogen amplification
EP2098590A1 (en) 2008-03-04 2009-09-09 ProBioGen AG Cell line from Rousettus as host cell for pathogen amplification
AU2009227674C1 (en) 2008-03-18 2015-01-29 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens
EP2310494A1 (en) * 2008-06-25 2011-04-20 ProBioGen AG Cell line for propagation of highly attenuated alphaviruses
EP2199385A1 (en) 2008-12-16 2010-06-23 ProBioGen AG Specific and persistent activation of heat shock response in cell lines using a viral factor
WO2010079081A1 (en) 2009-01-07 2010-07-15 Glaxosmithkline Biologicals S.A. Methods for recovering a virus or a viral antigen produced by cell culture
CA2750055A1 (en) 2009-02-06 2010-08-12 Glaxosmithkline Biologicals S.A. Method for purifying viruses using a density gradient
CA2752039A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
CA2752041A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
PL2396032T3 (pl) 2009-02-10 2017-05-31 Seqirus UK Limited Szczepionki przeciw grypie o obniżonych zawartościach skwalenu
BE1019643A3 (fr) 2009-04-27 2012-09-04 Novartis Ag Vaccins de protection contre la grippe.
HUE058971T2 (hu) 2009-07-15 2022-09-28 Glaxosmithkline Biologicals Sa RSV F fehérjekészítmények és eljárások azok elõállítására
EP2475385A1 (en) 2009-09-10 2012-07-18 Novartis AG Combination vaccines against respiratory tract diseases
WO2011040527A1 (ja) * 2009-09-30 2011-04-07 国立大学法人帯広畜産大学 α-ガラクトースエピトープを発現するトランスジェニック鳥類、ウイルス及びワクチン
WO2011095596A1 (en) 2010-02-04 2011-08-11 Vivalis Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
CN102791860A (zh) 2010-03-08 2012-11-21 诺华有限公司 检测胞内病原体的方法
WO2011127316A1 (en) 2010-04-07 2011-10-13 Novartis Ag Method for generating a parvovirus b19 virus-like particle
EP2563909A1 (en) 2010-04-26 2013-03-06 Novartis AG Improved production of virus replicon particles in packaging cells
CA2797059A1 (en) 2010-05-03 2011-11-10 Glaxosmithkline Biologicals S.A. Novel method
US9426989B2 (en) 2010-05-06 2016-08-30 Novartis Ag Organic peroxide compounds for microorganism inactivation
WO2011145081A1 (en) 2010-05-21 2011-11-24 Novartis Ag Influenza virus reassortment method
PL2575873T3 (pl) 2010-06-01 2016-06-30 Novartis Ag Zatężanie i liofilizacja antygenów szczepionkowych grypy
PL2575872T3 (pl) 2010-06-01 2021-02-22 Seqirus UK Limited Zatężanie antygenów szczepionkowych grypy bez liofilizacji
WO2012006293A1 (en) 2010-07-06 2012-01-12 Novartis Ag Norovirus derived immunogenic compositions and methods
EP2605792B1 (en) 2010-08-20 2014-12-10 Novartis AG Soluble needle arrays for delivery of influenza vaccines
JP2013544504A (ja) 2010-10-11 2013-12-19 ノバルティス アーゲー 抗原送達プラットフォーム
EP3257943B1 (en) * 2010-11-02 2019-09-11 Helmholtz-Zentrum für Infektionsforschung GmbH Methods and vectors for cell immortalisation
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
PL2667892T3 (pl) 2011-01-26 2019-09-30 Glaxosmithkline Biologicals Sa Schemat szczepień przeciwko rsv
ES2651143T3 (es) 2011-05-13 2018-01-24 Glaxosmithkline Biologicals Sa Antígenos de F de prefusión del VRS
US20140287402A1 (en) 2011-06-27 2014-09-25 Valneva Method for screening cells
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
WO2013006838A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
MX2014004214A (es) 2011-10-11 2014-05-07 Novartis Ag Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes.
WO2013054199A2 (en) 2011-10-12 2013-04-18 Novartis Ag Cmv antigens and uses thereof
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
WO2013057715A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
EP2660316A1 (en) 2012-05-02 2013-11-06 Helmholtz-Zentrum für Infektionsforschung GmbH Avian cell line and its use in production of protein
JP2015522580A (ja) 2012-07-06 2015-08-06 ノバルティス アーゲー 免疫学的組成物およびその使用
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
MX2015006377A (es) 2012-11-20 2015-07-21 Glaxosmithkline Biolog Sa Trimeros prefusion de f de vsr.
CN103060376A (zh) * 2012-12-11 2013-04-24 上海实验动物研究中心 一种禽腺病毒转移载体及其制备方法
CA2897752A1 (en) 2013-01-10 2014-07-17 Novartis Ag Influenza virus immunogenic compositions and uses thereof
US20140255447A1 (en) * 2013-03-05 2014-09-11 Biomune Company Production of avian embryo cells
EP3039127B1 (en) 2013-08-30 2020-01-01 GlaxoSmithKline Biologicals S.A. Large scale production of viruses in cell culture
CN104726409B (zh) * 2013-12-19 2017-12-29 普莱柯生物工程股份有限公司 一种永生化的鸭胚肝细胞系的制备方法和应用
US20150282503A1 (en) * 2014-04-02 2015-10-08 Synageva Biopharma Corp. Producing Therapeutic Proteins
EP2974739A1 (en) 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
EP3169341B1 (en) 2014-07-16 2019-06-05 Transgene SA Oncolytic virus for expression of immune checkpoint modulators
RU2694318C2 (ru) * 2014-12-04 2019-07-11 Интервет Интернэшнл Б.В. Иммортализованные фибробласты эмбриона цыпленка
EP3031822A1 (en) 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus antigens
JP6719468B2 (ja) 2014-12-16 2020-07-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 大規模なウイルス精製方法
PL3233130T3 (pl) 2014-12-17 2021-11-22 Fundacion Para La Investigacion Medica Aplicada Konstrukty kwasów nukleinowych i wektory do terapii genowej do zastosowania w leczeniu choroby wilsona
ES2784264T3 (es) 2014-12-17 2020-09-23 Fundacion Para La Investig Medica Aplicada Construcciones de ácido nucleico y vectores de terapia génica para su uso en el tratamiento de la enfermedad de Wilson y otras afecciones
EP3047856A1 (en) 2015-01-23 2016-07-27 Novartis AG Cmv antigens and uses thereof
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
US11013795B2 (en) 2015-06-26 2021-05-25 Seqirus UK Limited Antigenically matched influenza vaccines
JP6830070B2 (ja) 2015-07-07 2021-02-17 セキラス ユーケー リミテッドＳｅｑｉｒｕｓ ＵＫ Ｌｉｍｉｔｅｄ インフルエンザ効力アッセイ
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
CN107012122A (zh) * 2016-12-12 2017-08-04 江苏省农业科学院 一种永生化鸡胚胎肝细胞系及其制备方法和用途
ES2905478T3 (es) 2016-12-28 2022-04-08 Transgene Sa Virus oncolíticos y moléculas terapéuticas
WO2018176103A1 (en) 2017-03-30 2018-10-04 The University Of Queensland "chimeric molecules and uses thereof"
KR20240113607A (ko) 2017-06-21 2024-07-22 트랜스진 개인 맞춤형 백신
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
EP4400174A2 (en) 2017-09-01 2024-07-17 The Francis Crick Institute Limited Immunoregulatory molecules and uses therefor
EP3973973A1 (en) 2017-10-31 2022-03-30 KaliVir Immunotherapeutics, Inc. Platform oncolytic vector for systemic delivery
WO2019092002A1 (en) 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections
WO2019109051A1 (en) 2017-12-01 2019-06-06 Encoded Therapeutics, Inc. Engineered dna binding proteins
EP3794127A1 (en) 2018-05-14 2021-03-24 Vivet Therapeutics Gene therapy vectors comprising s/mar sequences
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
WO2020012037A1 (en) 2018-07-13 2020-01-16 Valneva Se Method for rescuing and producing a virus in avian cells
EP3617230A1 (en) 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
CN110396496B (zh) * 2018-09-30 2023-06-20 湖北省农业科学院畜牧兽医研究所 一种鸭小肠上皮细胞的培养方法及应用
WO2020074690A1 (en) 2018-10-12 2020-04-16 Vivet Therapeutics Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3)
BR112021008434A2 (pt) 2018-11-07 2021-09-28 Vivet Therapeutics Transgene abcb11 otimizado por códon para o tratamento de colestase intra-hepática familiar progressiva tipo 2 (pfic2)
CN109321516A (zh) * 2018-11-07 2019-02-12 贵州大学 一种鸭原代肝细胞分离及培养方法
WO2020102723A1 (en) 2018-11-16 2020-05-22 Encoded Therapeutics, Inc. Compositions and methods for treating wilson's disease
SG11202104869SA (en) 2018-11-23 2021-06-29 Valneva Se Food products comprising avian stem cells
SG11202106898VA (en) 2018-12-28 2021-07-29 Transgene Sa M2-defective poxvirus
EP3686276A1 (en) * 2019-01-28 2020-07-29 Freie Universität Berlin Production of viruses in continuously growing epithelial cell lines derived from chicken gut
AU2020299718A1 (en) 2019-07-02 2022-02-24 Fundacion Para La Investigacion Medica Aplicada cPLA2e inducing agents and uses thereof
CA3146900A1 (en) 2019-07-21 2021-01-28 Glaxosmithkline Biologicals Sa Therapeutic viral vaccine
US20230201334A1 (en) 2019-07-24 2023-06-29 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
JP2023502650A (ja) 2019-11-18 2023-01-25 セキラス ピーティーワイ リミテッド 遺伝子再集合インフルエンザウイルスを産生するための方法
WO2021209897A1 (en) 2020-04-13 2021-10-21 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
CA3189238A1 (en) 2020-07-13 2022-01-20 Transgene Treatment of immune depression
MX2023000968A (es) 2020-08-06 2023-03-01 Fundacion Para La Investig Medica Aplicada Particulas virales para usarse en el tratamiento contra tauopatias tales como enfermedad de alzheimer mediante terapia genica.
US20230265456A1 (en) 2020-08-10 2023-08-24 Fundacion Para La Investigacion Medica Aplicada Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis
JP2023544264A (ja) 2020-10-09 2023-10-23 ユーシービー バイオファルマ エスアールエル 核酸構築物、ウイルスベクター及びウイルス粒子
EP4267197A1 (en) 2020-12-23 2023-11-01 Vivet Therapeutics Minimal bile acid inducible promoters for gene therapy
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
WO2022149142A2 (en) 2021-01-10 2022-07-14 Supermeat The Essence Of Meat Ltd. Pluripotent stem cell aggregates and microtissues obtained therefrom for the cultured meat industry
EP4032547A1 (en) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce derived fragements for the treatment of hsv
BR112023022681A2 (pt) 2021-04-30 2024-01-23 Kalivir Immunotherapeutics Inc Vírus oncolíticos para expressão modificada de mhc
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
TW202321458A (zh) 2021-09-22 2023-06-01 瑞典商生物創新國際公司 新穎抗體組合及其用途
WO2023067595A1 (en) 2021-10-18 2023-04-27 Supermeat The Essence Of Meat Ltd. Methods for preparing a food ingredient and compositions produced thereby
CA3234666A1 (en) 2021-10-28 2023-05-04 UCB Biopharma SRL Nucleic acid constructs, viral vectors and viral particles
CN114350601B (zh) * 2021-12-21 2022-12-27 广东省华晟生物技术有限公司 樱桃谷鸭成纤维细胞系及其构建方法与应用
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
CN114908053A (zh) * 2022-04-24 2022-08-16 上海交通大学 孔雀成纤维永生化细胞系的制备方法及其在病毒扩增中的应用
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024038175A1 (en) 2022-08-18 2024-02-22 Transgene Chimeric poxviruses
CN116496992B (zh) * 2023-04-24 2023-12-01 江苏省家禽科学研究所 一种鸡胚成肌永生化细胞及其构建方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122614A0 (en) * 1995-06-15 1998-08-16 Introgene Bv Packaging systems for human recombinant adenovirus to be used in gene therapy
KR970010968A (ko) 1995-08-24 1997-03-27 윤원영 오리 배 세포를 이용한 에리스로포이틴의 발현 시스템
US5989805A (en) 1995-10-27 1999-11-23 Board Of Trustees Operating Michigan State University Immortal avian cell line to grow avian and animal viruses to produce vaccines
FR2749022B1 (fr) 1996-05-23 2001-06-01 Rhone Merieux Cellules aviaires immortelles
US5830723A (en) 1996-08-13 1998-11-03 Regents Of The University Of Minnesota Method for immortalizing chicken cells
US5672485A (en) 1996-08-13 1997-09-30 Regents Of The University Of Minnesota Immortalized cell lines for virus growth
FR2767335B1 (fr) 1997-08-14 2001-09-28 Ct Nat D Etudes Veterinaires E Adenovirus aviaire celo recombinant comme vecteur vaccinant
DE19955558C2 (de) * 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
CN1139655C (zh) * 2001-08-23 2004-02-25 北京大学人民医院 一种人卵巢癌永生化细胞株及其建立方法
DE60336653D1 (de) 2002-08-07 2011-05-19 Bavarian Nordic As Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren
NZ538575A (en) 2002-09-05 2007-03-30 Bavarian Nordic As Method for the amplification of a virus wherein primary avian cells are cultivated in a serum-free medium comprising growth factors and attachment factors
CA2531565C (en) 2003-07-22 2014-02-11 Vivalis Production of poxviruses with adherent or non adherent avian cell lines

Also Published As

Publication number Publication date
EP1939281A1 (en) 2008-07-02
RU2359999C2 (ru) 2009-06-27
KR20060123758A (ko) 2006-12-04
ES2309578T3 (es) 2008-12-16
WO2005042728A3 (en) 2005-07-07
CA2544462C (en) 2011-10-25
DK1939281T3 (da) 2010-06-14
WO2005042728A2 (en) 2005-05-12
SI1685243T1 (sl) 2008-12-31
RU2006119447A (ru) 2007-12-20
EP1685243B1 (en) 2008-06-18
EP1939281B1 (en) 2010-03-10
BRPI0415622A (pt) 2006-12-12
EP1939281B2 (en) 2014-06-04
PT1685243E (pt) 2008-09-24
KR101027755B1 (ko) 2011-04-07
DK1939281T4 (da) 2014-08-25
AU2004285089B2 (en) 2009-07-02
US20120288916A1 (en) 2012-11-15
CA2544462A1 (en) 2005-05-12
ATE460473T1 (de) 2010-03-15
EP1528101A1 (en) 2005-05-04
DK1685243T3 (da) 2008-10-20
BRPI0415622B8 (pt) 2021-05-25
CN1934243A (zh) 2007-03-21
DE602004014526D1 (de) 2008-07-31
ATE398672T1 (de) 2008-07-15
US8940534B2 (en) 2015-01-27
US20080227146A1 (en) 2008-09-18
DE602004025996D1 (de) 2010-04-22
EP2192173A1 (en) 2010-06-02
CN1934243B (zh) 2011-07-06
JP4658953B2 (ja) 2011-03-23
BRPI0415622B1 (pt) 2021-01-26
PL1685243T3 (pl) 2008-12-31
EP1685243A2 (en) 2006-08-02
AU2004285089A1 (en) 2005-05-12
JP2007510409A (ja) 2007-04-26

Similar Documents

Publication Publication Date Title
CY1110272T1 (el) Αθανατοποιημενες κυτταρικες σειρες πτηνων για παραγωγη ιου
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
CY1120911T1 (el) Παραγομενες απο mdck κυτταρικες σειρες προσαρμοσμενες σε απαλλαγμενη απο ορο καλλιεργεια και καλλιεργεια εναιωρηματος και μεθοδος για παρασκευη ιου εμβολιου χρησιμοποιωντας τα κυτταρα
CY1120622T1 (el) Μεθοδοι και συνθεσεις για επαγωγη μιας ανοσιακης αποκρισης ως προς egfrviii
CY1125338T1 (el) Λιποκατιονικα δενδριμερη και χρησεις εξ αυτων
WO2007048089A3 (en) Multi-plasmid system for the production of influenza virus
CY1111378T1 (el) Προερχομενα απο κυτταρα ιικα εμβολια με χαμηλα επιπεδα υπολειμματικου κυτταρικου dna
CY1119618T1 (el) Ενωσεις και συνθεσεις ως ρυθμιστικα μορια της tlr δραστηριοτητας
EP1697521A4 (en) PLASMID MULTIPLE SYSTEM FOR PRODUCING INFLUENZA VIRUS
EA200900784A1 (ru) Вакцины, включающие антиген из четырех штаммов вируса гриппа
CY1118072T1 (el) Συζευγματα cc-1065 αναλογων και διλειτουργικων αρθρωτων
NO20073737L (no) Hjelp for influensavirus
EA200801756A1 (ru) Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
CL2008003794A1 (es) Virus de la estomatitis vesicular geneticamente modificado (vsv) que comprende por lo menos una mutacion de aminoacido en una region de alguna de las proteinas m, g y l del virus; metodo para producirlo; composicion inmunogenica que lo comprende; metodo para adaptar un virus en un cultivo celular.
WO2005115448A8 (en) Multi plasmid system for the production of influenza virus
MX2021009554A (es) Produccion de virus en cultivos celulares.
CY1123144T1 (el) Επαγωγη καρδιακης αναγεννησης μe microrna
CY1116266T1 (el) Σταθερα αλατα της s-αδενοσυλμεθειονινης και μεθοδος παρασκευης τους
CY1123424T1 (el) Μεθοδος για την επικαλυψη σωματιδιων
MX2015016765A (es) Celulas aviares para la produccion mejorada de virus.
WO2014063016A8 (en) Methods for generating genetically superior animals
BR112016027818A2 (pt) composições purificadas de proteínas ivig e kh para modular linfócitos e tratar virus da hepatite b.
BR112018015527A2 (pt) métodos para produção de vírus
MX2024001464A (es) Vacunas de acido ribonucleico (arn).